Sign inJoin waitlistJoin the waitlist

Boris Juelg

Faculty · Mass General Brigham

Credentials: · · · · ·

History

Mass General Brigham
Present

Massachusetts General Hospital
2013–2015
Massachusetts General Hospital
2010–2011
Ludwig Maximilians University of Munich Medical School
2004–2007
Christian Albrechts University
2006

Research

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Nature · 2016 · 426 citations
Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022
JCI Insight · 2021 · 36 citations
High avidity CD8+ T cells efficiently eliminate motile HIV-infected targets and execute a locally focused program of anti-viral function
PLoS ONE · 2014 · 33 citations

BW
Bruce Walker
2 papers
Barry Zingman
1 paper
CL
Ching-Lan Lu
1 paper · 1 as a resident
Dan Barouch
1 paper
DW
Duane Wesemann
1 paper
Edward Kreider
1 paper
EM
Elizabeth McAndrew
1 paper
Julia Wagner
1 paper · 1 as a fellow
JL
Julie Ledgerwood
1 paper
LD
Leela Davies
1 paper
MC
Marina Caskey
1 paper
Michael Busch
1 paper

Grants

Multi-Omics Analysis of Broadly Neutralizing Antibodies and Therapeutic Vaccination
National Institute of Allergy and Infectious Diseases · P01
Project lead · $998.1K · Beth Israel Deaconess Medical Center
2023–2028
Ad26 Based Therapeutic Vaccines for HIV
National Institute of Allergy and Infectious Diseases · U01
PI · $9M · Beth Israel Deaconess Medical Center
2020–2027
Maternal Omics to Maximize Immunity
National Institute of Allergy and Infectious Diseases · U19
PI · $6.8M · Massachusetts Institute of Technology
2022–2027
Demystifying the Antiviral Activity of the IgG3+ Antibody Response
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $604.8K · Massachusetts General Hospital
2008–2025

Clinical trials

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults
Principal investigator · Completed · Phase 1, Phase 2
Boris Juelg, MD PhD
2022–2026
A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults
Principal investigator · Completed · Phase 1
International AIDS Vaccine Initiative
2018–2023
A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults
Principal investigator · Completed · Phase 1
International AIDS Vaccine Initiative
2017–2020
Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults
Study chair · Completed · Phase 1
International AIDS Vaccine Initiative
2016–2019